{
    "clinical_study": {
        "@rank": "85772", 
        "arm_group": [
            {
                "arm_group_label": "Clopidogrel", 
                "arm_group_type": "Active Comparator", 
                "description": "Antiplatelet monotheraphy : Clopidogrel"
            }, 
            {
                "arm_group_label": "Aspirin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Antiplatelet monotheraphy : Aspirin"
            }
        ], 
        "brief_summary": {
            "textblock": "Objectives :\n\n      To compare the efficacy and safety of clopidogrel monotherapy with aspirin monotherapy in\n      patients who received dual or triple antiplatelet therapy for 1 year (\u00b1 6 months) after\n      drug-eluting stent implantation for coronary artery disease\n\n      Patient Enrollment :\n\n      5500 patients enrolled at 55 centers in Korea\n\n      Patient Follow-up :\n\n      Clinical follow-up will occur at 1, 12 and 24 months.\n\n      Primary Endpoint :\n\n      composite of cardiovasculr death, myocardial infarction, stroke, severe/moderate bleeding,\n      readmission due to acute coronary syndrome, urgent revascularization\n\n      Secondary Endpoint :\n\n      Target vessel/lesion revascularization Stent thrombosis (acute, sub-acute, late, very late)\n      Peripheral vascular intervention"
        }, 
        "brief_title": "Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)", 
        "completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Coronary Stenosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject must be at least 20 years of age.\n\n          2. Subject who received dual or triple antiplatelet therapy for 1 year (\u00b1 6 months)\n             after drug-eluting stent implantation for coronary artery disease\n\n          3. Subject without clinical events during 1 year (\u00b1 6 months)\n\n          4. Subject who is confirmed to receive antiplatelet monotherapy (aspirin or clopidogrel)\n\n          5. Subject is able to verbally confirm understandings of risks, benefits and treatment\n             and he/she or his/her legally authorized representative provides written informed\n             consent prior to any study related procedure.\n\n          6. Subject is fertile woman and able to verbally confirm using effective methods of\n             contraception\n\n        Exclusion Criteria:\n\n          1. The patient has a known hypersensitivity or contraindication to aspirin or\n             clopidogrel.\n\n          2. Subject who cannot interrupt to receive antiplatelet drug.\n\n          3. History of bleeding diathesis or known coagulopathy requiring interruption of\n             antiplatelet drugs.\n\n          4. An elective intervention or surgical procedure is planned that would necessitate\n             long-term interruption of antiplatelet drugs during the study.\n\n          5. Liver function abnormality or renal failure\n\n               -  AST, ALT > 3 x UNL\n\n               -  Creatinine > 2.0 mg/dL\n\n          6. Non-cardiac co-morbid conditions are present with life expectancy < 2 years.\n\n          7. Subject who is pregnant, breastfeeding.\n\n          8. Subject who is not suitable to enroll the study decided by investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "5500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044250", 
            "org_study_id": "HOST-EXAM Trial"
        }, 
        "intervention": [
            {
                "arm_group_label": "Clopidogrel", 
                "intervention_name": "Clopidogrel (Copregrel / Plateless / Cloart / Pidogul)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aspirin", 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Ticlopidine", 
                "Clopidogrel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Aspirin", 
            "Clopidogrel", 
            "Antiplatelet monotherapy", 
            "Drug-eluting stent"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "contact": {
                "email": "bkkoo@snu.ac.kr", 
                "last_name": "Bon-Kwon Koo, MD, PhD", 
                "phone": "82-2-2072-2062"
            }, 
            "contact_backup": {
                "email": "hyosoo@snu.ac.kr", 
                "last_name": "Hyo-Soo Kim, MD, PhD", 
                "phone": "82-2-2072-2226"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Clopidogrel vs. Aspirin Monotherapy Beyond Two Year After Drug-eluting Stent Implantation", 
        "overall_contact": {
            "email": "bkkoo@snu.ac.kr", 
            "last_name": "Bon-Kwon Koo, MD, PhD", 
            "phone": "82-2-2072-2062"
        }, 
        "overall_contact_backup": {
            "email": "hyosoo@snu.ac.kr", 
            "last_name": "Hyo-Soo Kim, MD, PhD", 
            "phone": "82-2-2072-2226"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Hyo-Soo Kim, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Republic of Korea : Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "composite of cardiovasculr death, myocardial infarction, stroke, severe/moderate bleeding, readmission due to acute coronary syndrome, urgent revascularization", 
            "measure": "Composite of adverse cardiovascular outcomes", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044250"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Target vessel/lesion revascularization", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Stent thrombosis (acute, sub-acute, late, very late)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Peripheral vascular intervention", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Chong Kun Dang Pharmaceutical", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "SAMJIN PHARMACEUTICAL CO.,Ltd", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Daewoong Pharmaceutical Co. LTD.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "HANMI PHARMA CO.,Ltd", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}